Open-label extension of a phase II RCT: in 59 adults with alcohol use disorder, a single open-label psilocybin dose with therapy was well tolerated with no serious adverse events; drinking fell at month 1 in heavier drinkers but returned to entry levels thereafter.
Open-label extensionn = 59
Pagni et al. Safety and efficacy of psilocybin-assisted therapy for alcohol use disorder: Open-label extension of a phase II randomized controlled trial